Canada’s next defence frontier: Health emergency readiness as a sovereignty imperative

Canada’s new Defence Industrial Strategy commits to an ~85% increase in defence R&D investment over the next decade, a historic shift that rightly frames national security as an innovation challenge. The inclusion of life sciences in that agenda is a signals that the federal government understands what modern defence readiness requires. The opportunity now is to go further: treating the commercialization and adoption of biomedical innovation as a front-line defence capability, not just a health priority. The ability to manufacture diagnostics, develop vaccines, and scale biodefence therapeutics domestically is not only a health system issue –It is a defence issue, and it is imperative that Canada treat it as one. 

The pandemic made this visible in the most costly way possible. When supply chains collapsed, Canada could not produce what it needed at home. Our allies, including the US, UK, and key EU partners, have since moved aggressively to rebuild domestic biomedical manufacturing and commercialization capacity as explicit components of their national security strategies. Canada has invested in the science. We must scale our investment in the translational layer that turns that science into sovereign capability. 

World-class research. A critical commercial backbone. 

Ontario and Canada have the foundations of a world-leading life sciences ecosystem: globally competitive research institutions, top-tier teaching hospitals and deep scientific talent. Federal investments through the Canadian Institutes of Health Research (CIHR), Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF), among others, have established five national research hubs at the University of Alberta, University of British Columbia, Université de Montréal, McMaster University and the University of Toronto. The science is there. 

But discovery alone does not produce health security. The gap is commercialization, the structured, funded, connected pathway from lab bench to domestic supply chain. Our homegrown startups are developing the breakthroughs Canada needs: new therapies, diagnostics, vaccines and advanced medical technologies. But companies cannot scale without targeted support. Fragmented programming, underpowered commercialization services and capital gaps have been forcing too many to leave the country to grow – exporting IP, jobs, and returns on public investment as they go. This impacts not just Canada’s economy, but its sovereignty.

Life Sciences Central: A proven model for ecosystem infrastructure

Life Sciences Central – a partnership between MaRS Discovery District, OBIO®, and Toronto Innovation Acceleration Partners (TIAP) – was built to solve exactly this problem. It is a coordinated infrastructure model that consolidates access to commercialization resources, programming, funding, infrastructure, talent matching, IP support, advisory and connections to hospitals and procurement decision-makers. By integrating these critical resources into a single coordinated model, Life Sciences Central reduces friction caused by ecosystem fragmentation, allowing companies to scale with speed and focus. Critically, it is designed to be open, not gatekeeping, providing both self-serve access for the broader ecosystem and targeted support for high-potential, scale-ready ventures.  

“Ontario has world-class researchers, entrepreneurs and institutions. But we’ve long lacked the cohesive infrastructure to translate that excellence into scale-ready companies. Life Sciences Central addresses that gap by connecting the dots across our ecosystem lab space, capital, talent and commercialization support and making it easier for high-potential ventures to grow right here at home.” – Grace Lee Reynolds, CEO, MaRS Discovery District.

With a combined pipeline of more than 350 Canadian health companies, strategic alignment with a network of 200+ global investors and partnerships with the country’s leading research hospitals, Life Sciences Central demonstrates what it looks like when three leading organizations work in lockstep rather than in silos. The model is working. The question is whether the government will invest in scaling it nationally. 

“Together, we can eliminate inefficiencies, focus resources, and accelerate the journey for startups tackling some of the most urgent health challenges of our time. And in doing so, we can turn our research advantage into a commercial one, ensuring more life sciences innovations are developed, scaled and exported from right here at home.” –  Prakash Gowd, Interim President and CEO, TIAP

The policy ask: Align defence R&D with biomedical commercialization 

Canada’s Defence Industrial Strategy rightly identifies R&D as the foundation of long-term national security. But defence readiness in the 21st century extends beyond conventional military systems, equipment procurement and cybersecurity infrastructure. It includes supply chain resilience, domestic manufacturing capability and the biosecurity capacity to respond to public health emergencies, from pandemics to state and terrorist attacks, with made-in-Canada solutions. 

We are calling on the federal government to take three steps:

1. Align ISED and DND funding streams to explicitly support dual-use health and defence innovation, recognizing that biomedical commercialization infrastructure serves both civilian health and national security objectives. 
2. Create domestic procurement pathways for Canadian-developed therapeutics, diagnostics and vaccines, making the federal government a first customer for health innovations developed here, rather than a late adopter of foreign ones. 
3. Recognize innovation hubs as strategic national defence assets, not just economic development vehicles, and fund the commercialization infrastructure that connects Canada’s research excellence to its defence readiness agenda. 

“This is about unlocking Canada’s full economic and innovation potential, ensuring that more companies move from promising ideas to real-world health solutions, while creating jobs, IP and security wins that happen here rather than being exported to  global competitors.” – Dr. Maura Campbell, President and CEO, OBIO®.

Canada has the science. We have the proven ecosystem architecture. We have evidence, in Life Sciences Central, that coordinated commercialization infrastructure works. What we need now is policy that treats health emergency readiness as the defence priority it has always been – and  funding for  the translation layer that makes it real. 

The Defence Industrial Strategy is a historic opportunity. Seizing it fully means looking beyond conventional military systems and into the biological frontier of national security. The investments we make today in translating Canada’s health research excellence into domestic capability will determine whether we are a sovereign actor, or a dependent one, in the next crisis.